文献速递神经免疫

补体激活是MOGAD的突出特征

Complement Activation Is a Prominent Feature of MOGAD.
PubMed 文献 · Ann Neurol · 2021-10-09

该研究对比了成人和儿童MOGAD患者与复发型多发性硬化、视神经脊髓炎谱系疾病患者及健康对照者的系统性补体激活水平。结果显示MOGAD患者中提示经典途径和替代途径补体激活的蛋白显著升高,且见于所有临床综合征。作者建议探索补体抑制在MOGAD中的治疗价值。

要点

  • MOGAD患者存在系统性经典与替代补体途径激活。
  • 补体激活标志物升高见于成人和儿童及所有临床综合征。
  • 补体抑制应作为MOGAD的潜在治疗方向进行探索。

核心结论

  • 补体激活是MOGAD的突出特征,补体抑制值得探索其治疗价值。

研究设计与样本

  • 研究对比了成人和儿童MOGAD患者与复发型多发性硬化、视神经脊髓炎谱系疾病患者及儿童和成人健康供者的系统性补体激活谱。

主要发现

  • MOGAD患者中提示系统性经典和替代补体激活的蛋白较对照组显著升高。
  • 补体激活标志物升高见于成人和儿童MOGAD病例及所有临床综合征。

临床怎么用

  • 在MOGAD患者中可关注补体激活状态,并考虑补体抑制作为潜在治疗策略进行探索。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Myelin oligodendrocyte glycoprotein (MOG)-antibody (Ab)-associated diseases (MOGADs) account for a substantial proportion of pediatric and adult patients who present with acquired demyelinating disorders. Its pathogenesis and optimal therapy are incompletely understood. We profiled systemic complement activation in adult and pediatric patients with MOGAD compared with patients with relapse-onset multiple sclerosis, patients with neuromyelitis optica spectrum disorder, and pediatric control and adult healthy donors. Proteins indicative of systemic classical and alternative complement activation were substantially increased in patients with MOGAD compared to control groups. Elevated levels were detected in both adult and pediatric cases and across all clinical syndromes. Complement inhibition should be explored for its therapeutic merit in patients with MOGAD. ANN NEUROL 2021;90:976-982.

来源:Ann Neurol,查看原文。版权归原作者所有。

引用

  1. Keller CW, Lopez JA, Wendel EM, et al. Complement Activation Is a Prominent Feature of MOGAD. Ann Neurol. 2021. PMID: 34569094. doi:10.1002/ana.26226

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。